Core Insights - NeuroOne Medical Technologies Corporation has developed the OneRF® Ablation System, which has successfully treated a pediatric epilepsy patient, Clara Fuller, who previously experienced up to 10 seizures per night, resulting in her being completely seizure-free post-treatment [1][2][3] Company Overview - NeuroOne is focused on improving surgical care options for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain, through minimally invasive and high-definition solutions [4] - The company is exploring additional applications for its technology in areas such as depression, mood disorders, and pain management [4] Technology Impact - The OneRF® technology allows for minimally invasive radiofrequency ablation of seizure-causing brain tissue, significantly improving the quality of life for patients like Clara [2][3] - The successful treatment of Clara Fuller highlights the potential of the OneRF® platform to advance care for patients with debilitating neurological conditions [3]

Core Viewpoint - NeuroOne Medical Technologies Corporation has announced a public offering of 16,000,000 shares of common stock at a price of $0.50 per share, aiming to raise approximately $8,000,000 in gross proceeds for general working capital purposes [1][3]. Group 1: Offering Details - The offering consists entirely of shares sold by the Company, with an additional 45-day option for the underwriter to purchase up to 2,400,000 additional shares at the public offering price [2]. - The expected gross proceeds from the offering, before deductions, are $8,000,000, with the closing anticipated on or about April 7, 2025, subject to customary conditions [3]. Group 2: Regulatory Information - The shares will be issued under a shelf registration statement on Form S-3, which was declared effective by the SEC on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [4]. Group 3: Contact Information - For further inquiries, contact information for the MZ Group is provided, including a phone number and email address [7][8].

Company Overview - NeuroOne Medical Technologies Corporation is a medical technology company focused on improving surgical care options and outcomes for patients with neurological disorders [1][2]. Proposed Offering - The company has commenced a proposed underwritten registered public offering of shares of its common stock, with all shares to be sold by the company [1][2]. - The company intends to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares sold in the offering [2]. - The offering is subject to market and other conditions, with no assurance on the completion, size, or terms of the offering [2]. Underwriter Information - Ladenburg Thalmann & Co. Inc. is acting as the sole book-running manager for the proposed offering [3]. Regulatory Compliance - The proposed offering is made pursuant to a shelf registration statement on Form S-3, which was declared effective by the U.S. Securities and Exchange Commission on August 16, 2024 [4]. - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and made available on the SEC's website [4].

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The OneRF® Ablation System is a significant advancement in epilepsy treatment, being the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [3][4] Company Overview - NeuroOne is developing minimally invasive solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to enhance patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and high blood pressure [5] Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing medication-resistant seizures, highlighting the need for alternative treatment options like RF ablation therapy [2] - The OneRF® system offers a more efficient and precise approach for patients who do not respond to traditional medication, potentially reducing the need for multiple invasive surgeries [4]

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The company’s OneRF Ablation System is the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously, representing a significant advancement in epilepsy treatment [3][4] Company Overview - NeuroOne develops minimally invasive and high-definition solutions for EEG recording, brain stimulation, and ablation for conditions such as epilepsy, Parkinson's disease, and chronic pain [5] - The OneRF system includes an electrode for brain activity monitoring and ablation, a temperature probe, and a radio frequency heat generator [3] Market Context - Over 50 million people globally are affected by epilepsy, with about one-third experiencing medication-resistant seizures, highlighting the need for alternative treatments like RF ablation therapy [2] - The OneRF platform has potential applications beyond epilepsy, including pain management and other neurological disorders [4][5]

Core Insights - NeuroOne Medical Technologies Corporation is focused on improving surgical care options for patients with neurological disorders, particularly epilepsy, through innovative technology [1][5] - The OneRF® Ablation System is a significant advancement in epilepsy treatment, being the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [3][4] Company Overview - NeuroOne is developing minimally invasive solutions for EEG recording, brain stimulation, and ablation for various neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5] - The company aims to enhance patient outcomes and reduce procedural costs while exploring applications in other areas such as depression and high blood pressure [5] Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing medication-resistant seizures, highlighting the need for alternative treatment options like RF ablation therapy [2] - The OneRF® system offers a more efficient and precise approach for patients who do not respond to traditional medication, potentially reducing the need for multiple invasive surgeries [4]

Core Viewpoint - NeuroOne Medical Technologies Corporation is advancing epilepsy treatment through its innovative OneRF Ablation System, which combines brain activity monitoring and radiofrequency ablation in a single device, aiming to improve patient outcomes and reduce the need for multiple surgeries [1][4][3]. Company Overview - NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) focuses on developing minimally invasive and high-definition solutions for neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [5]. - The company is exploring applications for its technology in various areas such as depression, mood disorders, and high blood pressure [5]. Industry Context - Over 50 million people globally are affected by epilepsy, with nearly one-third experiencing seizures that do not respond to medication, highlighting the need for alternative treatment options like RF ablation therapy [2]. - The OneRF Ablation System is the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously, representing a significant advancement in the treatment of epilepsy [3].

Core Insights - NeuroOne Medical Technologies Corporation is addressing the needs of epilepsy patients who do not respond to traditional antiseizure medications, which affects approximately one million individuals in the U.S. alone [2][3] Company Overview - NeuroOne has developed the OneRF™ ablation system, the first FDA 510(k)-cleared device that can record brain activity and perform RF ablation simultaneously [4] - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5] Innovation and Impact - The OneRF™ system allows for a single hospitalization for both electrode placement and ablation, streamlining the treatment process compared to previous methods that required multiple invasive surgeries [5][6] - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, demonstrating its potential effectiveness [6] Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the U.S. [2] - NeuroOne is also exploring applications for other neurological disorders, including Parkinson's disease and chronic pain, which may improve patient outcomes and reduce procedural costs [8][9]

Core Insights - NeuroOne Medical Technologies Corporation is addressing the significant unmet need for non-pharmaceutical treatments for epilepsy, targeting the approximately one million patients who do not respond to current antiseizure medications [2][3]. Company Overview - NeuroOne has developed the OneRF™ ablation system, which is the first FDA 510(k)-cleared device capable of recording brain activity and performing RF ablation simultaneously [4]. - The OneRF™ system includes an electrode for monitoring brain activity, a temperature probe, and a radio frequency heat generation system, ensuring safe ablation temperatures [4][5]. Innovation and Impact - The OneRF™ system allows for a single hospitalization procedure, eliminating the need for multiple invasive surgeries and enabling real-time monitoring of the ablation's success [5][6]. - A case study highlighted a teenage patient who experienced significant seizure reduction after using the OneRF™ system, showcasing its potential to improve patients' quality of life [6]. Industry Context - Approximately 50 million people worldwide are affected by epilepsy, with over three million diagnosed in the US alone [2]. - The healthcare industry is increasingly focusing on innovative technologies that can provide more effective and personalized treatment options for neurological disorders [7]. Future Directions - NeuroOne is also exploring applications for other neurological conditions, including Parkinson's disease, chronic pain, and mood disorders, indicating a broader potential impact on patient care and procedural costs [9].

Core Viewpoint - NeuroOne Medical Technologies Corporation has accelerated its timeline for the 510(k) submission to the FDA for trigeminal nerve ablation, now expected in May 2025, utilizing its patented OneRF® Technology Platform, ahead of the previously projected June 2025 submission [1][3] Company Summary - NeuroOne is focused on developing minimally invasive medical technologies aimed at improving surgical care for patients with neurological disorders, including epilepsy, Parkinson's disease, and chronic pain [4] - The company has already achieved 510(k) FDA clearance for three product families and is now advancing its OneRF Trigeminal Nerve Ablation System [3] - If FDA clearance is obtained, the company anticipates potential revenue generation from trigeminal nerve ablation by late 2025, which was not previously expected within that calendar year [3] Industry Summary - Trigeminal nerve ablation is a minimally invasive procedure that uses radiofrequency energy to alleviate severe chronic facial pain caused by trigeminal neuralgia [2] - The market for trigeminal neuralgia therapeutics, which includes both pharmacologic and surgical technologies, is projected to grow from $262 million in 2024 to over $416 million by 2030, driven primarily by an aging population [2]